Pertussis vaccination during pregnancy: Antibody persistence in infants
| Tuesday, 2nd of August 2016 |
 |
 |
Vaccine. 2016 Jul 19;34(33):3719-22. doi: 10.1016/j.vaccine.2016.05.051. Epub 2016 Jun 11.
Pertussis vaccination during pregnancy: Antibody persistence in infants
Vilajeliu A1, Ferrer L2, Munrós J2, Goncé A2, López M2, Costa J3, Bayas JM4; PERTU Working Group.
- 1Department of Preventive Medicine and Epidemiology, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. Electronic address: albavilajeliu@gmail.com.
- 2Department of Maternal-Fetal Medicine, BCNatal - Barcelona Center of Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
- 3Department of Microbiology, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.
- 4Department of Preventive Medicine and Epidemiology, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Abstract
Maternal pertussis vaccination is associated with higher levels of pertussis antibodies at birth. We assessed the persistence of pertussisantibodies until primary vaccination in infants whose mothers received Tdap (tetanus, diphtheria, acellular pertussis) vaccine duringpregnancy. Infants were born at the Hospital Clinic of Barcelona (Spain) in November 2014. Anti-PT IgG was determined by ELISA at delivery, between the first and second month of life, and estimated at 2months of age. The study included 37 infants whose mothers received Tdap between 21 and 38weeks of gestation. Infants presented a decline in GMC of anti-PT IgG between peripartum and follow-up levels, 52.7 (95% CI 34.7-80.2) versus 7.5 (95% CI 4.2-13.3) at 2months of age (p<0.001). The median half-life of maternal antibodies was 47days. More than half (51.4%) the infants presented detectable anti-PT IgG before the start of primary infant vaccination.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
- Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial.[JAMA. 2014]
- Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants.[Clin Infect Dis. 2013]
- Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age.[Pediatr Infect Dis J. 2010]
- Review Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).[MMWR Recomm Rep. 2008]
- Review Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.[Drugs. 2012]
| Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
| Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
| Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
| Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
| Immunization Agenda 2030
Tuesday, 11th of February 2020 |
 |
41136229 |
| www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |